November 18, 2021 -- Bristol-Myers Squibb (BMS) has given its 2021 Golden Ticket awards to five startup biotechnology companies in recognition of their pursuit of research in novel target identification, drug delivery, discovery technology platforms, or translational R&D in a variety of therapeutic research fields.
The winners are as follows:
The winners receive one year of fully equipped, permitted, and supported lab space for biomedical research, plus programming and networking opportunities to help advance their science and build their companies, BMS said.
BMS launched its Golden Ticket program in 2016.